Kinnate Sells Pan-RAF Inhibitor Exarafenib To Pierre Fabre
05 Mar 2024 //
PRESS RELEASE
Kinnate Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre
01 Mar 2024 //
GLOBENEWSWIRE
First Report of +ve Dose Escalation Data Supports Best-in-Class Exarafenib
17 Apr 2023 //
GLOBENEWSWIRE